Literature DB >> 24614381

Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.

Julianne Kim1, Sandra A N Walker, Dolores C Iaboni, Scott E Walker, Marion Elligsen, Michael S Dunn, Vanessa G Allen, Andrew Simor.   

Abstract

Variability in neonatal vancomycin pharmacokinetics and the lack of consensus for optimal trough concentrations in neonatal intensive care units pose challenges to dosing vancomycin in neonates. Our objective was to determine vancomycin pharmacokinetics in neonates and evaluate dosing regimens to identify whether practical initial recommendations that targeted trough concentrations most commonly used in neonatal intensive care units could be determined. Fifty neonates who received vancomycin with at least one set of steady-state levels were evaluated retrospectively. Mean pharmacokinetic values were determined using first-order pharmacokinetic equations, and Monte Carlo simulation was used to evaluate initial dosing recommendations for target trough concentrations of 15 to 20 mg/liter, 5 to 20 mg/liter, and ≤20 mg/liter. Monte Carlo simulation revealed that dosing by mg/kg of body weight was optimal where intermittent dosing of 9 to 12 mg/kg intravenously (i.v.) every 8 h (q8h) had the highest probability of attaining a target trough concentration of 15 to 20 mg/liter. However, continuous infusion with a loading dose of 10 mg/kg followed by 25 to 30 mg/kg per day infused over 24 h had the best overall probability of target attainment. Initial intermittent dosing of 9 to 15 mg/kg i.v. q12h was optimal for target trough concentrations of 5 to 20 mg/liter and ≤20 mg/liter. In conclusion, we determined that the practical initial vancomycin dose of 10 mg/kg vancomycin i.v. q12h was optimal for vancomycin trough concentrations of either 5 to 20 mg/liter or ≤20 mg/liter and that the same initial dose q8h was optimal for target trough concentrations of 15 to 20 mg/liter. However, due to large interpatient vancomycin pharmacokinetic variability in neonates, monitoring of serum concentrations is recommended when trough concentrations between 15 and 20 mg/liter or 5 and 20 mg/liter are desired.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24614381      PMCID: PMC3993213          DOI: 10.1128/AAC.01718-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Antimicrobial susceptibilities of health care-associated and community-associated strains of methicillin-resistant Staphylococcus aureus from hospitalized patients in Canada, 1995 to 2008.

Authors:  Andrew E Simor; Lisa Louie; Christine Watt; Denise Gravel; Michael R Mulvey; Jennifer Campbell; Allison McGeer; Elizabeth Bryce; Mark Loeb; Anne Matlow
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

3.  Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.

Authors:  Yoke-Lin Lo; Johan G C van Hasselt; Siow-Chin Heng; Chin-Theam Lim; Toong-Chow Lee; Bruce G Charles
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

4.  The influences of renal function and maturation on vancomycin elimination in newborns and infants.

Authors:  E V Capparelli; J R Lane; G L Romanowski; E J McFeely; W Murray; P Sousa; C Kildoo; J D Connor
Journal:  J Clin Pharmacol       Date:  2001-09       Impact factor: 3.126

5.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.

Authors:  Brian J Anderson; Karel Allegaert; John N Van den Anker; Veerle Cossey; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2006-07-21       Impact factor: 4.335

7.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in Canada.

Authors:  Kimberly A Nichol; Heather J Adam; Diane L Roscoe; George R Golding; Philippe R S Lagacé-Wiens; Daryl J Hoban; George G Zhanel
Journal:  J Antimicrob Chemother       Date:  2013-05       Impact factor: 5.790

8.  Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.

Authors:  Helio S Sader; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

9.  The clinical pharmacology of vancomycin in seriously ill preterm infants.

Authors:  M D Reed; R M Kliegman; J S Weiner; M Huang; T S Yamashita; J L Blumer
Journal:  Pediatr Res       Date:  1987-09       Impact factor: 3.756

10.  Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.

Authors:  Arta Balode; Volga Punda-Polić; Michael J Dowzicky
Journal:  Int J Antimicrob Agents       Date:  2013-04-13       Impact factor: 5.283

View more
  9 in total

1.  Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight.

Authors:  Hiroshi Sasano; Kanon Aoki; Ryutarou Arakawa; Kazuhiko Hanada
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

2.  Dosing antibiotics in neonates: review of the pharmacokinetic data.

Authors:  Nazario D Rivera-Chaparro; Michael Cohen-Wolkowiez; Rachel G Greenberg
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.553

Review 3.  Antimicrobial Stewardship in the Neonatal Intensive Care Unit: An Update.

Authors:  Despoina Gkentzi; Gabriel Dimitriou
Journal:  Curr Pediatr Rev       Date:  2019

4.  Population pharmacokinetics and dose optimization of vancomycin in neonates.

Authors:  Soon Min Lee; Seungwon Yang; Soyoung Kang; Min Jung Chang
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

5.  Vancomycin Prescribing Practices and Therapeutic Drug Monitoring for Critically Ill Neonatal and Pediatric Patients: A Survey of Physicians and Pharmacists in Hong Kong.

Authors:  Twinny Cheuk Hin Chow; Janice Yuen Shun Li; Jasper Chak Ling Wong; Freddie Man Hong Poon; Hugh Simon Lam; Teddy Tai-Ning Lam; Chui Ping Lee; Celeste Lom-Ying Ewig; Yin Ting Cheung
Journal:  Front Pediatr       Date:  2020-11-30       Impact factor: 3.418

6.  Practical approaches to improve vancomycin-related patient outcomes in pediatrics- an alternative strategy when AUC/MIC is not feasible.

Authors:  Kashif Hussain; Muhammad Sohail Salat; Shahzad Rauf; Manoj Rathi; Midhat Khan; Fizzah Naz; Wasif Ahmed Khan; Rahila Ikram; Gul Ambreen
Journal:  BMC Pharmacol Toxicol       Date:  2022-08-20       Impact factor: 2.605

7.  Index for the appropriate vancomycin dosing in premature neonates and infants.

Authors:  Aiju Endo; Atsushi Nemoto; Kazumi Hanawa; Takahiro Ishikawa; Mai Koshiishi; Yuki Maebayashi; Yohei Hasebe; Atsushi Naito; Yoshifumi Kobayashi; Katsuhiko Isobe; Yayoi Kawano; Takehisa Hanawa
Journal:  Pediatr Int       Date:  2021-11-22       Impact factor: 1.617

8.  Vancomycin is commonly under-dosed in critically ill children and neonates.

Authors:  Natasha Sosnin; Nigel Curtis; Noel Cranswick; Roberto Chiletti; Amanda Gwee
Journal:  Br J Clin Pharmacol       Date:  2019-08-30       Impact factor: 4.335

9.  Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?

Authors:  Roberta Maia de Castro Romanelli; Lêni Márcia Anchieta; Juliana Chaves Abreu Fernandes; Mariana Antunes Faria Lima; Taís Marina de Souza; Viviane Rosado; Wanessa Trindade Clemente; Paulo Augusto Moreira Camargos
Journal:  Braz J Infect Dis       Date:  2016-08-12       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.